“Kronos Bio was founded with a clear vision: to tackle the challenge of deregulated transcription, a hallmark of cancer,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio. “To best meet this challenge, we pursued a multi-pronged strategy using our proprietary product engine to map TRNs, find their key modulators, and identify novel drug candidates targeting those modulators. Simultaneously, we used our TRN mapping capabilities to identify existing clinical assets that we could acquire to accelerate our development efforts, such as lanraplenib. While we’re disappointed not to bring lanraplenib forward, it’s exciting to see our discovery efforts lead to the designation of a second internally discovered development candidate.”
